Please ensure Javascript is enabled for purposes of website accessibility

Exact Sciences Beat Expectations in Q1: Why Investors Didn't Jump for Joy

By Keith Speights - May 5, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was a big asterisk with the company's improved bottom line.

Exact Sciences (EXAS 0.83%) hasn't delivered the sizzling performance so far in 2021 that it did last year. That hasn't stopped Cathie Wood from scooping up more shares of the molecular diagnostics company for her ARK Innovation ETF (ARKK 4.19%).

Wood might have an opportunity to buy more shares at a bigger discount. Exact Sciences announced its first-quarter results after the market closed Tuesday. The healthcare stock slipped around 1.5% in after-hours trading. Here are the highlights from Exact Sciences' Q1 update.

Exact Sciences' Cologuard kit.

Image source: Exact Sciences.

By the numbers

Exact Sciences reported revenue in the first quarter of $402.1 million. This result reflected a 16% increase from the prior-year period revenue total of $347.8 million. It also easily topped the Wall Street consensus revenue estimate of $388.5 million.

The company announced a Q1 net loss of $31.2 million, or $0.18 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Exact Sciences posted a GAAP net loss of $134.6 million, or $0.91 per share. The average analysts' estimate was for an adjusted net loss of $1.03 per share.

Exact Sciences ended the first quarter with cash, cash equivalents, and short-term investments of $1.38 billion. At the end of 2020, the company's cash position stood at $1.84 billion.

Behind the numbers

Exact Sciences makes around 60% of its total revenue from screening, including its Cologuard colorectal cancer tests and its Biomatrica products. The company recorded screening revenue in the first quarter of $240.3 million, up 10% year over year.

Precision oncology revenue totaled $129.4 million in Q1, a 1% year-over-year increase. This revenue includes sales of Exact Sciences' Oncotype tests used to optimize treatment decisions for breast, colon, and prostate cancer. The company also recorded COVID-19 testing revenue of $32.3 million in the first quarter.

There's a big asterisk with Exact Sciences' improved bottom line. The company had an income tax benefit of $242.8 million in Q1. Without this benefit, its net loss would've been much worse. That's likely why shares slipped a little despite Exact Sciences beating Wall Street estimates.

Looking ahead

Exact Sciences expects full-year 2021 revenue of between $1.69 billion and $1.735 billion. Screening revenue is projected to generate between $1.125 billion and $1.15 billion of that total. The company anticipates precision oncology revenue of between $515 million and $525 million. COVID-19 testing revenue is projected to come in between $50 million and $60 million.

CEO Kevin Conroy said, "The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future." He also hinted at the company's development pipeline, stating, "We plan to bring additional solutions to patients throughout the course of their diagnosis and treatment."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
$42.71 (0.83%) $0.35
ARK ETF Trust - ARK Innovation ETF Stock Quote
ARK ETF Trust - ARK Innovation ETF
$52.01 (4.19%) $2.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.